Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Bernard, Marie Clotilde ^a   Barban, Véronique ^a   Pradezynski, Fabrine ^a   De Montfort, Aymeric ^a   Ryall, Robert ^a   Caillet, Catherine ^a   Londono Hayes, Patricia ^a  

^a SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HERPES SIMPLEX VACCINE; HSV529 VACCINE; INTERLEUKIN 5; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; GLYCOPROTEIN D-HERPES SIMPLEX VIRUS TYPE 2; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GENITAL HERPES; GUINEA PIG; HERPES SIMPLEX VIRUS 1; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RESISTANCE; LATENT VIRUS INFECTION; MORTALITY; MOUSE; NONHUMAN; VIRUS MUTANT; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS VIRULENCE; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECTS; GENETICS; HERPES GENITALIS; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNIZATION; IMMUNOLOGY; SCID MOUSE; SECRETION (PROCESS); SURVIVAL ANALYSIS; TH1 TH2 BALANCE; VAGINA; VIROLOGY; VIRUS LATENCY;

ANIMALIA; CAVIA; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; MUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; GUINEA PIGS; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; INTERFERON-GAMMA; INTERLEUKIN-5; MICE; MICE, SCID; SURVIVAL ANALYSIS; TH1-TH2 BALANCE; VAGINA; VIRAL ENVELOPE PROTEINS; VIRUS LATENCY; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 84926671943     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121518     Document Type: Article

References (15)

1. Hofstetter AM, Rosenthal SL, Stanberry LR Current thinking on genital herpes. CurrOpin Infect Dis. 2014;27:75-83. doi: 10.1097/QCO.0000000000000029 PMID: 24335720
2. Looker KJ, Garnett GP, Schmid GP An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection.. Bull World Health Organ. 2008;86:805-812, A. PMID: 18949218
3. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies.. AIDS. 2006;20:73-83. PMID: 16327322
4. Wald A, Link K Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis.. J Infect Dis. 2002;185:45-52. PMID: 11756980
5. Johnston C, Saracino M, Kuntz S, Magaret A, Selke S, Huang ML, et al. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet. 2012;379:641-647. doi: 10.1016/S0140-6736 (11) 61750-9 PMID: 22225814
6. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347:1652-1661. PMID: 12444179
7. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, et al. Efficacy results of a trial of a herpes simplex vaccine. N EnglJ Med. 2012;366:34-43. doi: 10.1056/NEJMoa1103151 PMID: 22216840
8. Hoshino Y, Dalai SK, Wang K, Pesnicak L, Lau TY, Knipe DM, et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol. 2005;79:410-418. PMID: 15596834
9. Mundle ST, Hernandez H, Hamberger J, Catalan J, Zhou C, Stegalkina S, et al. High-purity preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivo. PLoSOne. 2013;8:e57224. doi: 10.1371/journal.pone.0057224 PMID: 23468943
10. Da Costa X, Kramer MF, Zhu J, Brockman MA, Knipe DM Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2.. J Virol. 2000;74:7963-7971. PMID:10933704
11. Delagrave S, Hernandez H, Zhou C, Hamberger JF, Mundle ST, Catalan J, et al. Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model. PLoSOne. 2012;7:e46714. doi: 10.1371/journal.pone.0046714 PMID: 23071620
12. Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, Straus SE, et al. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositiveand HSV-1-seronegative guinea pigs. J Infect Dis. 2009;200:1088-1095. doi: 10.1086/605645 PMID: 19702506
13. Hoshino Y, Pesnicak L, Dowdell KC, Lacayo J, Dudek T, Knipe DM, et al. Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine. 2008;26:4034-4040. doi: 10.1016/j.vaccine.2008.05.022 PMID: 18565628
14. Da Costa XJ, Jones CA, Knipe DM Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection.. Proc Natl Acad Sci USA. 1999;96:6994-6998. PMID: 10359827
15. Awasthi S, Zumbrun EE, Si H, Wang F, Shaw CE, Cai M, et al. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. J Virol. 2012;86:4586-4598. doi: 10.1128/JVI.07203-11 PMID: 22318147